Beta Bionics, Inc. reported second-quarter 2026 results with revenue rising to $32M while the company posted a net loss of $23.4M, or diluted EPS of $(0.53), compared with revenue of $23.2M and a net loss of $16.9M, or $(0.39) per share, in the year-ago quarter.
Financial Highlights
- Revenue: $32.0M for 2Q 2026, up from $23.2M in 2Q 2025 (38% YoY).
- Net income: Net loss $23.4M for 2Q 2026, versus net loss $16.9M in 2Q 2025 (worse by $6.5M YoY).
- Diluted EPS: $(0.53) for 2Q 2026, versus $(0.39) in 2Q 2025 (declined YoY).
Business Highlights
- Year-to-date net sales rose 46% to $59.6M, driven by increased single-use product sales and new patient starts.
- Channel mix shifted toward pharmacy benefit plan (PBP) distribution, with PBP share growing to 37% YTD from 21% a year earlier; company is prioritizing pharmacy reimbursement.
- iLet adoption showed strong uptake among multiple daily injection (MDI) users, accounting for roughly 70% of new adoption and signaling product-market fit and a simplified value proposition.
- Company scaled U.S. commercial operations, customer support and manufacturing capacity to support growth and development of the Mint patch pump.
- Regulatory and operational work continues, including remediation efforts related to an FDA Warning Letter and advancement of Mint patch pump and bihormonal trials toward pivotal stages.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.